COLL

Collegium Pharmaceutical, Inc.

Fundamental data last updated:November 5, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Drug Manufacturers - Specialty & Generic

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

11/05/2026

Business Summary

Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions. A prominent offering is Xtampza ER, an extended-release, oral formulation of oxycodone, specifically engineered with properties to deter abuse. This particular drug is prescribed for patients experiencing severe, persistent pain that necessitates daily, continuous, long-term opioid therapy. The company's portfolio also encompasses Nucynta ER and Nucynta IR, which are extended-release and immediate-release versions of tapentadol, respectively. Founded in 2002, the enterprise initially operated under the name Collegium Pharmaceuticals, Inc., before officially adopting its current identity as Collegium Pharmaceutical, Inc. in October 2003. The company's corporate headquarters are situated in Stoughton, Massachusetts.

 


Analyze COLL on TradingView

VALUATION

P/E

15.48

Market Cap ($M USD)

$770.92M

Forward P/E

3.17

PEG

-97.90

PRICE TO SALES

0.95

PRICE TO BOOK

2.46

EV / EBITDA

3.17

5-Year Average P/E

Free Cash Flow Yield

42.58%

DCF Value

$660.35

Graham Number

$17.86

Price to FCF

2.35

EV to FCF

4.57

Earnings Yield

6.23%

FCF Yield

42.58%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$1.48

Next Year EPS Growth Estimate

$7.46

Next Year Revenue Growth Estimate

$833.11M

Return on Equity (ROE)

15.96%

FREE CASH FLOW

Operating Margin

19.61%

Debt-to-Equity

2.75

Piotroski F-Score

5

Altman Z-Score

0.95

Return on Invested Capital (ROIC)

6.10%

Current Ratio

1.03

Quick Ratio

0.84

Net Debt to EBITDA

1.54

Interest Coverage

0.98

Gross Profit margin

60.02%

FCF PER SHARE

$10.11

REVENUE PER SHARE

$24.90

Analyze COLL on TradingView

Gainseekers Quantitative Analysis

Summary

Collegium Pharmaceutical’s valuation is a paradox. Despite a DCF value that towers over its snapshot price, the market seems skeptical, perhaps due to its precarious Altman Z-score of 0.94, signaling potential distress. The Forward P/E of 3.11 suggests the market expects explosive earnings growth, yet the Earnings Yield of 6.36% indicates a cautious stance. This stock is priced for a turnaround, but its financial health raises red flags about its ability to deliver on those expectations. Investors must weigh the allure of deep value against the specter of financial instability.

AI Exposure / Tech Reliance

In the realm of AI and tech adaptation, Collegium Pharmaceutical operates within the healthcare sector, where innovation is crucial. As a drug manufacturer, its ability to integrate AI for drug discovery and personalized medicine could be pivotal. However, its current metrics don't explicitly highlight a tech-forward strategy, leaving its adaptability an open question.

The Bull Case

For the value-driven investor, Collegium offers a compelling narrative. With a robust ROIC of 6.10% and a healthy FCF Yield of 43.45%, the company demonstrates strong capital efficiency and cash generation. The Piotroski F-Score of 5 indicates moderate financial health, while an operating margin of 19.61% underscores its pricing power. These metrics suggest a company capable of delivering shareholder value through disciplined financial management and operational efficiency.

The Bear Case

Yet, the bear case is equally persuasive. The company's Debt/Equity ratio of 2.75 raises alarms about its leverage, compounded by an interest coverage ratio below 1, suggesting potential liquidity issues. Trading at a Price/Book of 2.42 and Price/Sales of 0.93, the stock isn't exactly cheap, especially given its proximity to the 52-week high. The technical overextension and structural financial weaknesses could deter risk-averse investors.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$48.00

Institutional Ownership %

1-Year Beta

0.73

Insider Buying % (6 Mo)

Distance to 52-Week High

114.48%

Distance to 52-Week Low

9.50%

EARNINGS SURPRISE %

11.63%

50-DAY SMA

$23.30

200-DAY SMA

$33.24

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.